Nitric oxide synthase 3 messenger RNA (NOS3 mRNA)

Nitric oxide synthase 3 (NOS3) mRNA is the messenger RNA transcript that encodes the endothelial nitric oxide synthase (eNOS) enzyme, which is the primary source of nitric oxide (NO) in the vascular endothelium (NCBI Gene ID: 4846). NO produced from this pathway is essential for maintaining vascular tone, preventing platelet aggregation, and protecting against leukocyte adhesion to the vessel wall (UniProt P29474). Reduced expression or stability of NOS3 mRNA is a key feature of endothelial dysfunction, contributing significantly to the development of hypertension, atherosclerosis, and other cardiovascular disorders. In the context of modern pharmacology, NOS3 mRNA is being explored as a therapeutic target for mRNA replacement therapies, where synthetic modified mRNA is delivered to tissues to restore functional eNOS protein levels (Masuda et al., 2017). While no mRNA-based drugs for NOS3 are currently FDA-approved, experimental studies have demonstrated the potential of this approach to improve blood flow and promote tissue repair in ischemic conditions. Additionally, the transcript is a frequent target in research using RNA interference (siRNA) to investigate the physiological roles of nitric oxide signaling.

Other names

eNOS mRNAEndothelial nitric oxide synthase mRNANOS III mRNANitric oxide synthase 3 transcript

mRNA replacement therapy (translation into functional eNOS protein to restore nitric oxide production) or RNA interference (targeted degradation of the transcript to study or modulate enzyme levels).